FDA weighs esketamine for depression
Feb 15, 2019•6 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Contact us: [email protected]
- FDA panels back intranasal esketamine for refractory depression.
http://bit.ly/2TOKrfp - ONC aims to help doctors, patients with information sharing in proposed rule.
http://bit.ly/2X3SVkP - Survey: Health care costs unlikely to improve in 2019.
http://bit.ly/2SwSIYJ - Vaccination and antiviral treatment don't lower stroke risk after shingles.
http://bit.ly/2tjYQVa
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast